New prostate cancer treatment can cause more harm than good

Prostate cancer is a huge worry for men. And rightly so—as one out of every nine men will be diagnosed with it at some point in their lives.

In most cases, though, these men really have what I call “fake” prostate cancer, with just a few biopsied cells that look abnormal under a microscope. But, even left untreated, these cells would never invade adjacent tissue or metastasize. Nor would they shorten a man’s life. (Remember, most men die with prostate cancer, not because of it.)

And sadly, more and more men are bullied into receiving aggressive, life-changing treatments for these fake cancers.

Worse yet…

The mainstream is even failing to really help the small percentage of men who have metastatic prostate cancer—the kind of prostate cancer that does spread and does kill men. In fact, I’m especially wary of one “exciting,” new treatment for men with this deadly kind of prostate cancer…

New prostate cancer treatment sends up all kinds of red flags

The latest offering for men with metastatic prostate cancer is the radiopharmaceutical drug lutetium (Lu-177). It’s a radioactive agent that men receive as an intravenous infusion. Then, the radioactive particles float around the body, looking for cancer.

Of course, the makers of Lu-177 say the agent only targets and destroys cancer cells.

But I have my doubts…

For one, the drug actually targets Protein Specific Membrane Antigen (PMSA), a receptor that’s found in high concentrations on the surface of prostate cancer cells. But it’s also found on healthy prostate cells. In fact, it’s even expressed in other healthy cells around the body, including the small intestine, kidneys, and salivary glands.

So, in my view, attacking PMSA will probably turn out to cause more harm than good.

Of course, we don’t have any final results from the trials, which are still being conducted at locations around the country, including Cornell Medical Center in New York, UCSF in San Francisco, and UCLA in Los Angeles.

But I can guarantee you this…

Researchers will learn about the effects on the cancer first…and then, later, they’ll find out about all its complications. (As is the case with the prostate drugs linked to Type II diabetes, which I discussed yesterday.)

So, while the researchers are calling Lu-177 an “exciting treatment” (after all, what could possibly go wrong with injecting radioactive molecules to circulate throughout the body?)…it’s far better to prevent prostate cancer in the first place by making some simple dietary and lifestyle changes. You can start by adding these five foods to your diet—today!

In addition, you can learn everything you need to know about how to NATURALLY conquer prostate cancer in my new, comprehensive, science-backed Insider’s Ultimate Guide to Perfect Prostate Health. Click here to learn more about this innovative learning protocol or sign up today.

P.S. Tune back in Thursday for a new report on lung cancer.

Source:

“Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy.” J Med Radiat Sci. 2017 Mar; 64(1): 52–60. doi: 10.1002/jmrs.227

“PSMA Emerges as Versatile Target in Prostate Cancer and Beyond.” OncLive, 6/19/19. (onclive.com/publications/oncology-live/2019/vol-20-no-12/psma-emerges-as-versatile-target-in-prostate-cancer-and-beyond)


CLOSE
CLOSE